This site is intended for health professionals only

HIV drug available to more patients


The All Wales Medicines Strategy Group (AWMSG) has extended recommendations for the use of an HIV drug.

Isentress (raltegravir; Merck, Sharpe & Dohme) can now be used by those who cannot take these types of medicines due to drug-drug interactions (PDF, 190k) or in combination with other antiretroviral medicines, for the treatment of HIV-1 infection in any adults who are resistant to or intolerant of non-nucleoside reverse transcriptase inhibitors or protease inhibitors.

However, the recommendations made by the AWMSG in 2008 for the use of the drug in treatment-experienced adults still applies.

The AWMSG has ruled that the prescribing of Revatio should be restricted to a doctor experienced in treating this condition in association with a National Commissioning Group-designated expert centre.

Also recommended for use within its current licensed indication to improve the exercise capacity of patients with pulmonary arterial hypertension (PDF, 150K), is hypertension drug Revatio (sildenafil; Pfizer).

Copyright Press Association 2010

All Wales Medicines Strategy Group

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine